Beyond the Headlines: FDA Warning Letters to GLP 1 Compounders Spencer Fane The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP 1 Drugs, and a Compounding Pharmacy Operating Without Control The Unregulated World of Peptides: A Legal Minefield for Providers Holt Law FDA mulls compounding for peptides previously flagged over safety risks BioSpace